Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
08/05/2026 16:54
May 8 (Reuters) - Odyssey Therapeutics ODTX.O shares rose 11.1% in its Nasdaq debut on Friday, giving the biopharmaceutical firm a valuation of $899.9 million. (Reporting by Prakhar Srivastava in Bengaluru; Editing by Vijay Kishore) ((Prakhar.srivastava2@thomsonreuters.com;))
Recent news on Kailera Therapeutics
See all newsChina biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection